Psoriatic Alopecia and Paradoxical Psoriasis Induced by Adalimumab Successfully Treated with Certolizumab: Clinical, Trichoscopic, and in vivo Reflectance Confocal Microscopy Features.

Authors :: Megna M
De Lucia M
Gallo L
Lauro W
Picone V
Fabbrocini G
Ocampo-Garza SS
Source :: Skin appendage disorders [Skin Appendage Disord] 2023 Jun; Vol. 9 (3), pp. 207-210. Date of Electronic Publication: 2022 Dec 08.
Publication Year :: 2023
Abstract: Introduction: Psoriatic alopecia is considered a type of hair loss occurring in patients with psoriasis. Adalimumab is a fully humanized recombinant anti-TNF-alpha monoclonal antibody approved for treatment of psoriasis and psoriatic arthritis (PsA), rarely related to the occurrence of dermatological disorders.<br />Case Presentation: We report the case of a 56-year-old female with PsA developing psoriatic alopecia and paradoxical psoriasis induced by adalimumab and successfully treated switching to certolizumab, evaluating response at both thrichoscopy and in vivo reflectance confocal microscopy.<br />Discussion: Among anti-TNF-α agents, certolizumab is the least involved in the development of paradoxical reactions such as psoriatic alopecia and showed to be an effective and safe alternative therapeutic options to manage psoriasis and PsA minimizing the risk of paradoxical reactions.<br />Competing Interests: The authors have no conflicts of interest to declare.<br /> (Copyright © 2022 by S. Karger AG, Basel.)

Full Text Access

Tools